Neuvivo, a biopharmaceutical company dedicated to ALS treatments, has initiated cGMP manufacturing of NP001 for the treatment of ALS (Lou Gehrig’s Disease).  The company expects to have product available by the end of the year for clinical use.    NP001 received FDA’s Fast Track and Orphan Drug designation.  It has been shown to be safe and effective in clinical trials. Data show a 38% slowing of disease progression as measured by ALSFRS-R score and importantly, a 51% slowing of th...